Exo has secured an $11.6 million grant from the Gates Foundation, announced November 19, to develop an affordable, multipurpose handheld ultrasound system for frontline health workers in low- and middle-income countries. The grant, reported by Citybiz, is philanthropic funding rather than venture capital, and comes on top of roughly $428 million the company has raised across ten prior financing rounds.
What Exo builds
Exo makes handheld ultrasound devices built around proprietary piezoelectric silicon imaging chips paired with on-device artificial intelligence. The AI runs locally on the handheld unit rather than in the cloud, guiding users through image acquisition and helping interpret scans in real time — a design choice that matters in regions where internet connectivity is unreliable or absent. CEO Sandeep Akkaraju said the approach is meant to make ultrasound "more affordable and easier for frontline healthcare workers to use," even without specialized sonography training.
That focus on untrained operators sets Exo's grant-funded project apart from its existing commercial product line, which has targeted hospitals and clinics in wealthier markets since the company's $220 million Series C in 2021.
How the money will be used
The Gates Foundation grant is earmarked specifically for next-generation imaging technology aimed at closing diagnostic gaps tied to equipment cost, specialist shortages, procedural complexity and spotty connectivity — all barriers that have kept ultrasound largely out of reach for frontline clinics in poorer countries. Rather than funding sales expansion, the grant is structured as development money for a stripped-down, lower-cost device variant suited to that market.
Competitors and how this compares
Exo's closest rival in handheld, AI-guided ultrasound is Butterfly Network, which received its own $5 million Gates Foundation grant in 2022 for maternal and fetal health work in low-resource settings. The parallel grants suggest the Gates Foundation sees AI-guided point-of-care ultrasound as one of the more promising near-term tools for expanding diagnostic imaging in places that will never have a radiology department, rather than betting on a single vendor. Exo's $428 million in prior venture funding dwarfs the size of this grant, underscoring that the money here is about product adaptation for a new market segment, not a funding lifeline.
What to watch next
The near-term question is how quickly Exo can get a lower-cost, offline-capable device variant into the hands of community health workers, and whether the Gates Foundation's involvement helps it secure distribution through public health systems in target countries. Expect comparisons to Butterfly Network's grant-funded maternal health work to sharpen as both companies report results from their respective low-resource deployments.